Comparative Pharmacology
Head-to-head clinical analysis: EUTHROID 0 5 versus EUTHROID 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EUTHROID 0 5 versus EUTHROID 3.
EUTHROID-0.5 vs EUTHROID-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Euthyroid-0.5 is a combination of liothyronine (T3) and levothyroxine (T4). T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors (TRα and TRβ) in the nucleus, regulating gene transcription involved in metabolism, growth, and development.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Oral: 0.5 grains (30 mg) once daily, titrated to clinical response.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal and hepatic function; clinically, steady-state is reached within 24-36 hours, and dosing interval adjustments may be needed in renal or hepatic impairment.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Renal (approx. 20-40% as unchanged drug, primarily via glomerular filtration and tubular secretion); biliary/fecal (approx. 60-80% as metabolites and unchanged drug, with enterohepatic recirculation).
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Category C
Category C
Thyroid Hormone Replacement
Thyroid Hormone Replacement